Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Beta-blockers for hypertension.

C S Wiysonge1, H Bradley, B M Mayosi

  • 1Ministry of Public Health, EPI, BP 25125 Messa, Yaoundé, Cameroon. wiysonge@yahoo.com

The Cochrane Database of Systematic Reviews
|January 27, 2007
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Establishing the African region monitoring vaccine effectiveness (AFRO-MoVE) network for respiratory pathogens.

Vaccine·2025
Same author

Behavioural and social drivers of human papillomavirus vaccination in eThekwini District of KwaZulu-Natal Province, South Africa.

PloS one·2024
Same author

COVID-19 vaccine hesitancy in South Africa: A complex social phenomenon.

South African medical journal = Suid-Afrikaanse tydskrif vir geneeskunde·2022
Same author

Zirconia implants: a promising alternative to titanium?

Evidence-based dentistry·2021
Same author

Role of vaccines in preventing influenza in healthy children.

South African medical journal = Suid-Afrikaanse tydskrif vir geneeskunde·2021
Same author

Presentation and non-surgical endodontic treatment of two patients with X-linked hypophosphatemia: a case report.

International endodontic journal·2021
Same journal

Interventions for smoking cessation in inpatient psychiatry settings.

The Cochrane database of systematic reviews·2026
Same journal

Mechanical thromboprophylaxis for preventing intradialytic hypotension in people undergoing maintenance haemodialysis.

The Cochrane database of systematic reviews·2026
Same journal

Prognostic models for predicting intensive care unit admission or mortality in critically ill adults not yet been admitted to the intensive care unit.

The Cochrane database of systematic reviews·2026
Same journal

Views and experiences of weight management for people living with mobility‑limiting conditions, intellectual disabilities or severe mental illness: a qualitative evidence synthesis.

The Cochrane database of systematic reviews·2026
Same journal

Non-pharmacological interventions for anxiety and depression in Parkinson's disease.

The Cochrane database of systematic reviews·2026
Same journal

Biologic drugs for induction and maintenance of remission in Crohn's disease: a network meta-analysis.

The Cochrane database of systematic reviews·2026
See all related articles

Beta-blockers are not recommended as first-line hypertension treatment due to limited stroke reduction and worse outcomes compared to other drug classes. Evidence suggests they are less effective and have more side effects than calcium-channel blockers and RAS inhibitors.

Area of Science:

  • Cardiology
  • Pharmacology
  • Clinical Trials

Background:

  • Previous reviews suggest beta-blockers are less effective than other antihypertensives for stroke and major adverse events.
  • Comparisons with combined drug classes may obscure differential effects of beta-blockers against specific drug classes.
  • Tolerability of beta-blockers relative to other antihypertensives requires further assessment.

Purpose of the Study:

  • To quantify the effectiveness and safety of beta-blockers as first-line therapy for hypertension.
  • To compare beta-blockers against placebo, diuretics, calcium-channel blockers (CCBs), and renin-angiotensin system (RAS) inhibitors.

Main Methods:

  • Systematic review and meta-analysis of 13 randomized controlled trials (N=91,561).
  • Inclusion of trials comparing beta-blockers as monotherapy or first-line therapy for hypertension.

Related Experiment Videos

  • Data extraction and analysis using fixed or random effects models based on heterogeneity, with results expressed as relative risks (RR) and 95% confidence intervals (CI).

    • Main Results:

    • Beta-blockers showed no difference in all-cause mortality compared to placebo, diuretics, or RAS inhibitors, but a higher risk than CCBs.
    • Total cardiovascular disease (CVD) risk was lower than placebo, primarily due to reduced stroke, but higher than CCBs.
    • Increased stroke risk was observed compared to CCBs and RAS inhibitors; higher discontinuation rates due to side effects were noted for diuretics and RAS inhibitors.

    Conclusions:

    • Evidence does not support beta-blockers as first-line hypertension treatment due to limited stroke reduction and absence of effect on coronary heart disease.
    • Worse outcomes were observed compared to CCBs, RAS inhibitors, and thiazide diuretics.
    • Further research is needed to determine differential effects across patient subgroups and beta-blocker subtypes.